Cancer/Oncology Drugs Market Size, Production Capacity, Healthcare Infrastructure Growth, Product Utilization, Regulatory Compliance, Sales Analysis, and Investment Trends

Revenue, 2025

USD 192.39 Bn

Forecast Year, 2035

USD 554.69 Bn

CAGR, 2026 - 2035

11.17%

Report Coverage

Global

What is the Cancer/Oncology Drugs Market Size?

The global cancer/oncology drugs market size is calculated at USD 192.39 billion in 2025 and is predicted to increase from USD 214.70 billion in 2026 to approximately USD 554.69 billion by 2035, expanding at a CAGR of 11.17% from 2026 to 2035. The fuelling trust for proteomics technology and the targeted therapies conviction are accelerating the market growth. The systematic momentum of drug alteration is a pathway to the core cancer research theory that finalizes the efficacy and safety of the oncology drugs.

Cancer/Oncology Drugs Market Key Takeaways

• North America led the global market with the highest market share of 45% in 2025.
• By class type, the targeted therapy segment has held the largest market share of 50% in 2025.
• By indication, the lung cancer segment captured the biggest revenue share in 2025.

Market Overview

The cancer/oncology drugs are a medication catalogue specifically consumed for cancer and malignant tumors. The right impact of the dosages are the only solution to the provided cancer therapies, as there's no one-size-fits-all solution for cancer, as it's a crucial condition. For the same, advances have arrived in the therapies and drug regimen. Popular therapies like hormone, immunotherapy, targeted, and chemo involve different sets of medications suitable to the cancer type. These drugs meet the treatment goals to additionally mitigate the pain and symptoms level to calm the patient. The disturbed cancer population is receiving the advanced solution with the effective drug formula, which revives the lost hope of this population. The drug-to-drug solution acceptance is a boon to the healthcare providers to proceed with this classic mechanism hidden from science so far.

How is AI contributing to the Cancer/Oncology Drugs Market?

AI plays a major role in the development of oncology drugs by revealing the potential of drugs, forecasting how different compounds will act, and allowing the repurposing of already existing molecules. AI makes a more accurate diagnosis by spotting fine tumor patterns in imaging, which in turn enhances the accuracy of the diagnosis. Moreover, AI significantly reduces the entire development time and helps to advance cancer treatment based on data quickly.

Cancer/Oncology Drugs Market Growth Factors

The global cancer drugs market is primarily driven by the increasing prevalence of various types of cancer among the global population. As per the GLOBOCAN, a report published by the International Agency for Research on Cancer, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be recorded in 2040 across the globe. The most prominent types of cancer include lungs cancer, breast cancer, prostate cancer, and colorectal cancer. Moreover, the rapid developments in the biopharmaceutical market has resulted in the development of various new and innovative drugs that can efficiently target the cancer cells without harming the normal cells. The increased awareness among the population regarding the availability of various advance therapeutics to treat cancer is significantly driving the growth of the global cancer drugs market. The rising investments by various pharmaceutical companies in the research and development of various new cancer drugs is expected to provide new growth avenues in the forthcoming future.

Cancer/Oncology Drugs Market Outlook

• Industry Growth Overview: The rising number of oncology patients and therapy innovations are the main factors driving the growth.
• Sustainability Trends: The use of non-toxic drugs, environmentally friendly methods in drug production, and the green chemistry approach will be the new trends in the development of cancer drugs.
• Global Expansion:Treatment accessibility and awareness are the main factors contributing to the strong pathways for oncology adoption worldwide.
• Major Investors: The activities of F. Hoffmann-La Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, and Johnson are the factors that always make the market grow.
• Startup Ecosystem: New companies in the oncology field are now developing inexpensive diagnostic tools, AI-assisted therapy, online cancer treatment, and academic collaboration for their innovations.

Market Scope

Cancer/Oncology Drugs Market Segment Insights

Class Type Insights

What Factors Drove Targeted Therapy to Lead the Cancer Drugs Market in 2025?

The targeted therapy segment dominated the market by over 50% in 2025, in terms of revenue. The targeted therapy involves the use of drugs that precisely targets the cancer affected cells in the body and prevents the normal cells from getting damaged or affected. This results in minimal side-effects. The advantages of the targeted therapy over the traditional chemotherapy has fostered the demand for the targeted therapy across the globe. The chemotherapy involved higher risks of internal organ failure, re-occurrence of cancer, and other harmful side-effects that sometimes resulted in death. Therefore, the development of the targeted therapy, which is much more efficient and low toxic than the chemotherapy has gained rapid traction among the cancer patients and hence dominated the cancer drugs market.

On the other hand, the immunotherapy is estimated to be the fastest-growing segment during the forecast period. The rapidly rising awareness regarding the benefits of the monoclonal antibodies used in the cancer immunotherapy is boosting the adoption of the immunotherapy among the population. Moreover, the rising number of approvals by the authorities like EMA and FDA is fueling the growth of the immunotherapy. In 2017, the FDA and EMA collectively approved around 73 monoclonal antibodies.

Indication Insights

What Factors Contributed to Lung Cancer Leading the Market in 2025?

The lung cancer segment accounted largest revenue share in 2025. This is attributed to the increased prevalence of the lungs cancer across the globe. Lungs cancer is the most prominent type of cancer that affects the majority of the global population. According to the International Agency for Research on Cancer, around 1.8 million deaths were recorded due to lungs cancer in 2020. Lungs cancer is the leading cause of the cancer deaths that accounts for around 18% of the global cancer deaths.

On the other hand, the breast cancer is estimated to be the most opportunistic segment during the forecast period. The rapidly rising cases of breast cancer amongst the female population is driving the growth of this segment.According to the International Agency for Cancer Research,around 2.3 million or 11.7% of the new cancer cases reported as the breast cancer in 2020. The breast cancer has surpassed the lungs cancer as the most diagnosed type of cancer across the globe. Therefore, this segment is expected to grow rapidly in the forthcoming years.

Cancer/Oncology Drugs Market Regional Insights

How is North America leading in the Cancer/Oncology Drugs Market?

The market consists of multiple factors, such as healthcare spending, infrastructure, high diagnosis rates, and fast adoption of therapy, which make it the biggest market. Furthermore, research pipelines and the supportive cancer treatment environment are driving the expansion of precision medicine and, hence, of drug development.

U.S. Cancer/Oncology Drugs Market Size and Growth 2026 to 2035

The U.S. cancer/oncology drugs market size is estimated at USD 60.70 billion in 2025 and is expected to be worth around USD 161.29 billion by 2034, at a CAGR of 11.25% from 2026 to 2035.

Based on region, North America accounted highest revenue share in 2023. This is attributed to the higher prevalence of cancer cases in North Americaalong with the increased adoption of the cancer drugs amongst the American population. According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The colorectal cancer, lungs cancer, prostate cancer, and breast cancerare the most prominent types of cancers that affects the majority of the population in the US. The presence of developed healthcare infrastructure, higher healthcare expenditure, and the favorable reimbursement policies have fostered the market growth in the Region. However, due to the higher adoption of the cancer drugs in the US, the cancer deaths has declined by 29% since 1991.

United States Cancer/Oncology Drugs Market Trends

The U.S. takes the lead with a major focus on precision oncology and a good number of clinical trials. The supportive programs and innovation-based research collaborations are the driving forces behind the development of new therapies and the making of rare cancer research more accessible.

What are the driving factors of the Cancer/Oncology Drugs Market in Europe?

The continent with its well-established healthcare systems is the one that most supports the adoption of personalized medicine and biosimilars. Changes in the regulations have extended access to new oncology drugs, and they will also boost the development of more and more targeted drugs in different cancer areas.

On the other hand, Europe is estimated to be the most opportunistic market during the forecast period. This is attributable to the growing cancer cases and cancer deaths across the Europe. According to the European Commission, approximately 2.7 million new cancer cases and about 1.3 million cancer deaths were recorded in 2020. The people aged 65 years or above were the most affected by the cancer in in 2020, across Europe. Breast cancer was the most diagnosed type of cancer across the European nations in 2020.

Germany Cancer/Oncology Drugs Market Trends

The large pharmaceutical industry is facilitated with reimbursement support. The key growth area is the immunotherapy uptake, which is backed by active research funding and the broadening of innovation in clinical oncology.

How is Asia-Pacific performing in the Cancer/Oncology Drugs Market?

The region is expected to have the highest growth due to the aging population, more healthcare investments, and the improvement of the medical facilities. With the increase in local innovation, the region is becoming a place for conducting oncology trials.

China Cancer/Oncology Drugs Market Trends:

The oncology market in China is growing fast, and the country is supporting R&D while also making approvals easier. Collaborations with international firms and the inclusion of innovative drugs in reimbursement programs are just some of the opportunities.

Latin America's Precision Strategies in the Market

Latin America market is considered to be a significantly growing area, due to its precision oncology promises that involve the valuable role of biomarkers in clinical settings. Precision therapy is a success story in the regional healthcare records. The research teams have stored a bunch of valuable data that can be considered in the next-generation cancer drug pipeline. The flow of research is the biggest strength for the regional market's proven expansion. Following this, the anti-cancer drugs will soon gain traction in the oncology drug industry. The accessibility of targeted therapy allows this industry to showcase its potential in oncology treatments.

Brazil Market Trends

Brazil's medical trends have observed a transition after 2021 as the development has met the cancer patient population's needs. The smart trends consist of the services and manufacturing industries. Further Brazilians safe agriculture is for the betterment of the public healthcare systems. This concentration is in favor of the community that creates awareness of the proper food plan with limitations. The death graph is the concerned area for the Brazilians, and so consistent transitions are highly initiated by the regional healthcare leaders. This elevates the opportunity scope for cancer medicines as well.

MEA's Business Expansion in the Market

MEA market is expected to grow at a notable CAGR in the foreseeable future. The businesses are boosted by the availability of compatible formulations that supports the advance drug delivery patterns that directly target cancer cells. The heavy investment in cancer research highlights the advocacy of essential drugs. The emphasis on the new polyphenolic drugs is said to be the next blockbuster hit of the regional market.

UAE Market Trends

UAE market trends are all about drug accessibility and safety. Access to affordable therapies is a boon for the cancer patient population. Advancements in research have developed a strong thesis for drug management to further add value to the commendable treatments.

Cancer/Oncology Drugs Market Value Chain Analysis

• R&D: Focuses on discovering and testing new drug compounds and therapeutic applications.
  Key Players: F. Hoffmann-La Roche Ltd, Novartis International AG, Merck & Co., Inc., AstraZeneca PLC
• Clinical Trials & Regulatory Approvals: Conducts human studies to prove safety and efficacy for approvals.
  Key Players: Bristol-Myers Squibb Company, Johnson & Johnson, and Pfizer Inc.
• Formulation & Final Dosage Preparation: Converts API into a stable, patient-ready medication form.
  Key players: Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla Limited
• Packaging & Serialization: Protects product and ensures integrity through traceable tracking codes.
  Key players: Amcor plc, Gerresheimer AG, Schott AG, West Pharmaceutical Services, Inc
• Distribution: Manages logistics to hospitals and pharmacies for oncology drug delivery.
  Key players: McKesson, AmerisourceBergen, Cardinal Health

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

In April 2020, F.Hoffmann-La Roche launched Atezolizumab, an immunotherapy medicine in India, for the treatment of breast cancer.

The various developmental strategies like new product launches, acquisitions, and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Cancer/Oncology Drugs Market Companies

• Amgen: Advances the treatment of solid tumors and blood cancers by developing targeted medicines and immunotherapies based on BiTE technology.
• Bayer Healthcare AG: Targets therapies for different types of solid tumors, including prostate, liver, and digestive tract cancer.
• Celgene Corporation: Offered blood cancer treatments such as Revlimid, Pomalyst, and Abraxane before the Merger with Bristol Myers Squibb.

Other Major Key Players

• GlaxoSmithKline
• ARIAD Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis
• Hoffmann-La Roche Ltd.
• AstraZeneca
• BoehringerIngelheim GmbH
• Pfizer
• Teva Pharmaceuticals Industries

Recent Developments

• In August 2025, GlaxoSmithKline launched two precision therapies, Jemperli and Zejula, in India for treating gynaecological cancers, emphasizing its entry into the oncology market.
  (Source: newindianexpress.com)
• In August 2025, N-Power Medicine launches the ProECA platform to innovate oncology drug development, reducing patient enrollment by 50%, shortening trials by 6-12 months, and cutting costs significantly.
  (Source: www.businesswire.com)

Segments Covered in the Report

By Drug Class

• Targeted Therapy
• Chemotherapy
• Hormonal Therapy
• Immunotherapy

By Indication

• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World